von Willebrand disease (VWD) is a common autosomal-dominant inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF), a multiadhesive protein which binds platelets to exposed subendothelium, participates in platelet aggregation and carries factor VIII in circulation. VWD is classified into six different types (►Table 1). Type 1 and 3 VWD reflect the partial or complete quantitative deficiency of VWF, respectively, while four type 2 variant reflect different qualitative defects of VWF.
1 Type 2 displays a wide heterogeneity of functional abnormalities reflecting the location of the causative mutations in the VWF protein.
1
Among type 2 variants, VWD type 2B (VWD2B) is unique because of its peculiar pathophysiology and laboratory phenotype.
2 This was first shown by Ruggeri et al who identified a group of VWD patients, now classified as type VWD2B, with variable reduction of plasma VWF, but with in vitro ristocetin-induced platelet agglutination (RIPA) occurring at concentrations lower than those required for normal controls and other patients with VWD. 3 Subsequently, a lack of high-molecular-weight (HMW) multimers of VWF in plasma was observed and attributed to a heightened interaction of the abnormal VWF with the physiological glycoprotein (Ib-α; GpIb-α) receptor on platelet membrane. 4 Furthermore, increasing plasma concentration of this mutant protein by administering desmopressin (DDAVP) could induce a variable degree of thrombocytopenia, which was however, already present at baseline in a significant proportion of patients.
5,6
VWD2B is a rare ($3% of all VWD cases), usually highly penetrant autosomally inherited bleeding disorder caused by gain-of-function mutations in A1 domain of VWF.
6 Around 50% of patients with this type exhibit mild-to-moderate thrombocytopenia, which can be unraveled or further aggravated by some clinical circumstances (e.g., surgery, infection, 
How Type 2B VWF Influences Platelets
Patients with some mutations (e.g., I1309V, V1316M) are particularly prone to develop thrombocytopenia at baseline or after triggering clinical situations, 6 while in others it does not occur at all (e.g., P1266Q/L or 3923G>T R1308L). Thrombocytopenia inversely correlates with the increase of circulating levels of conformational active form of type 2B VWF, which may also interact spontaneously with GpIb-α
6
Apart from affecting the interaction with GPIb-α, recent findings suggest that 2B VWF may also affect platelet production. In addition to platelet aggregates, in peripheral blood smears of VWD2B patients giant platelets may also be evident. 6, 12 Of note, recently it has been shown that the disorder previously called Montreal platelet syndrome, characterized by thrombocytopenia with large platelets and bleeding symptoms, is indeed caused by the V1316M VWF mutation. 13 Megakaryocytes from patients with VWD2B have an altered morphology and produce abnormal and fewer platelets than normal controls, suggesting that the continuous interaction with GpIb-α of abnormal VWF during megakaryocytes maturation influences the formation of platelets in these patients. 14 Recently, in a murine model for VWD2B, which reproduces the phenotype observed in human patients with the disorder, Casari et al found that murine VWD2B platelets, again depending on the type of mutation, have a variably shorter circulatory survival than wild-type platelets, which could contribute to the lower platelet count in VWD2B mice. 15 This underlines the role of VWF-type 2B in inducing the formation of abnormal platelets with shortened lifespan in circulation. Importantly, further analysis revealed that VWF-type 2B is exclusively present at the surface of platelets of thrombocytopenic VWD2B mice, suggesting that VWF binding to platelets is needed to induce thrombocytopenia.
15 These VWF-platelet complexes are taken up efficiently by macrophages in the liver and spleen, thus accelerating their clearance. 16, 17 Interestingly, increase of circulating levels of conformational active form of 2B VWF also promotes VWF binding by macrophages. Macrophage depletion leads to a two-to threefold increase of platelet counts in thrombocytopenic mice with type 2B V1316M mutation, characterized by the most severe thrombocytopenia. 15 Furthermore, it was recently found that activation of VWF via exposure to shear stress, enhances macrophage uptake, thus contributing significantly to the clearance of VWF.
17
Thus, thrombocytopenia in VWD2B appears to be the result of at least a combination of shortened survival of the abnormal platelets and of an accelerated clearance of the abnormal VWF/platelet complexes by macrophages in the liver and spleen.
18 VWD2B appears to not only be a disorder of a plasma hemostatic protein, but also of platelets, suggesting that, in addition to VWF/factor VIII concentrates, transfusion of normal platelets may be justified in VWD2B patients with bleeding and worsening of their thrombocytopenia due to hemostatic stress situations.
18
Furthermore, recent studies from the same group demonstrated that also platelet dysfunction is present in VWD2B.
19
A dysregulated platelet signaling upon binding to GpIb-α, which severely impairs platelet aggregation, secretion and platelet spreading was in fact demonstrated on the basis of a decreased activation of the platelet fibrinogen integrin receptor αIIbβ3 as a consequence of type 2B VWF binding to GpIb-α. This altered platelet function would of course add to increase the risk of bleeding carried by low VWF with loss of HMW multimers and thrombocytopenia. 20 
Proteolysis and Clearance of Type 2B Von Willebrand Factor
Loss of HMW multimers in VWD2B is due to increased ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) proteolysis. 21 Furthermore, low-density lipoprotein receptor-related protein 1 (LRP1) plays a major role in shear-dependent macrophage-mediated clearance of VWF, and binds VWF exclusively under conditions of elevated shear-stress forces. 16, 17, 22 It has been demonstrated that the VWF A1 domain contains an interactive site for LRP1 and that the degree of this site exposure is modulated by peculiar VWD2B mutations.
23
Recent evidence has been provided to show that some VWD2B mutations display shear-stress independent binding to LRP1. 23 Furthermore, in a mouse model macrophage-LRP1
contributes to increased clearance of R1306Q and V1316M in vivo even without shear stress, explaining the increased clearance of these type 2B mutations.

Laboratory Diagnosis
A wide heterogeneity of laboratory phenotypes is evident in VWD2B, being strictly associated with the causative mutation. The hallmark unifying all the different types of mutations, however, is the evidence of an heightened response to low concentrations of ristocetin in the RIPA assay. Usually, the laboratories screen for VWD2B by using a ristocetin concentration of 0.5 mg/mL and a response is defined as the concentration of ristocetin able to induce at least 30% of the aggregation amplitude after 3 minutes from its addition to patient's platelet rich plasma. This occurs at higher doses than 0.5 mg/mL with some mutations (e.g., P1266L) while at lower doses (even 0.3 mg/mL) with others (V1316M). Variable reduction of plasma VWF antigen (VWF:Ag) and VWF ristocetin cofactor (VWF:RCo) is observed, but also normal levels have been reported and VWF:RCo/VWF:Ag ratio may also be normal, at variance with type 2A and type 2M. Also, FVIII may be normal or only slightly reduced. There is a tendency for fluctuating levels of both VWF:RCo and VWF:RCo/VWF:Ag ratio according to the degree of ongoing type 2B VWF-platelet interaction. 6 Loss of HMW and sometimes intermediatemolecular-weight multimers is typically present in patients with the mutations more frequently associated with thrombocytopenia (V1316M, R1308C) 6 while the profile is normal in patients with the previously defined New York/Malmoe subtype (P1266L). 6, 10, 11 In keeping with the demonstrated increased binding to specific LPR1 receptors, VWF propeptide to VWF:Ag ratio is increased, 22 which represents a sensitive index of increased VWF clearance.
24,25
VWD2B must be distinguished from a platelet disorder expressing similar laboratory phenotype, named platelet-type VWD (PT-VWD), in which gain-of-function mutations in platelet GpIb-α similarly cause loss of plasma HMW VWF multimers, variable thrombocytopenia, and enhanced RIPA.
26,27 Several laboratory methods have been developed to discriminate between the two disorders, including cryoprecipitate challenge and simplified RIPA mixing assays, 27 but only the identification of specific mutations in GP1BA gene will clarify the different pathophysiology. 28 In addition, recent evidences suggest that the bleeding tendency is milder in PT-VWD patients.
29
VWD2B should be always considered in the presence of inherited chronic thrombocytopenia with large platelets on blood smear. This would also help to avoid misleading therapeutic approaches, including corticosteroids and splenectomy, as observed in the experience of the authors (G.C. and A.B., data not shown). Furthermore, in those patients with thrombocytopenia, family studies could help showing the high consistency of platelet count abnormality associated with the lifelong bleeding tendency. according to the responsible mutation and this means that when enhanced RIPA is detected mutation detection is of utmost importance in identifying the patients more at risk of significant bleeding (►Table 3). Recurrent gastrointestinal bleeding associated with gastrointestinal angiodysplasia has also been described. 30 Pregnancy in VWD2B can cause or worsen thrombocytopenia and platelet transfusions have been used at parturition in some patients.
31,32
VWF replacement therapy is usually required for VWD2B patients, especially in those with the mutations at risk of significant bleeding and/or thrombocytopenia. Dose and timing of administration are similar to what is usually advised in other VWD types requiring substitutive treatment. 33 The goal of treatment in patients undergoing major surgery is to maintain FVIII and VWF (typically using VWF:RCo as the laboratory parameter) plasma levels around 80 to 100 IU/dL for at least a couple of days and trough level above 50 IU/dL for an additional 5 to 7 days thereafter. A loading dose of 50 IU/kg of VWF:RCo is usually given in severe cases 30 minutes to 1 hour before surgery, followed by similar daily doses for the next 2 days. A single or daily doses for 2 to 3 days of 20 to 60 IU/kg of VWF:RCo (depending on the severity of bleeding) are hemostatically effective for treating spontaneous bleeding episodes or for preventing bleeding during invasive procedures. It should be kept in mind, however, that in some situations with ongoing bleeding there could be a worsening of thrombocytopenia because of increased stimulation of the release of the abnormal VWF from endothelial cells and blood count, especially platelets, should be closely monitored. In the past, there have been reports of possible clinical effectiveness of DDAVP in a few cases of VWD2B patients, without significant thrombocytopenia 34 and there is clear evidence that some mutations (P1266L, R1308L) do not show any platelet decrease after DDAVP administration. 6 However, the compound should be used cautiously and probably best avoided in patients already displaying thrombocytopenia at baseline or with mutations known to be associated with possible aggravation of thrombocytopenia.
Alloantibodies to VWF are rare and reported to occur mainly in type 3 patients in whom no VWF is synthesized in association with homozygous null mutations, including gene deletions. 35 However, the occurrence of alloantibodies to VWF in a patient with VWD2B (R1308C mutation) after substitutive treatment has been recently reported. 36 Interestingly, the antibody specificity seems to be restricted toward the active platelet-binding conformation of the A1 domain of VWF. 36 Following this report, it appears that closely monitored measurement of FVIII/VWF activities after substitutive treatment is advised, especially after intensive treatment in previously minimally treated patients.
Conclusions
VWD2B represents a rare, but fascinating bleeding disorder, which displays a wide heterogeneity of laboratory and clinical phenotypes. The interaction of type 2B VWF and platelet production and function is worthy of further studies to elucidate this complex interaction. Identifying the responsible VWD2B mutation appears relevant not only to distinguish it from the PT-VWD, but also to predict the severity of bleeding tendency and type of treatment.
